Astonea Labs Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astonea Labs Ltd is ₹ 160.05 as of 30 Apr 15:30 . The P/E Ratio of Astonea Labs Ltd is 0 as of March 2023 .The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 . The Market Cap of Astonea Labs Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Astonea Labs Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 years .

About Astonea Labs Ltd

Astonea Labs Limited was originally incorporated as 'AHU Laboratories Private Limited', as a private limited company, pursuant to certificate of incorporation dated April 11, 2017.
Company changed its name from AHU Laboratories Limited to 'Astonea Labs Private Limited' dated February 26, 2019.
Subsequently, the Company further changed the name to 'Astonea Labs Limited', vide fresh Certificate of Incorporation dated January 11, 2024. Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products.
These include antibiotic drugs, anticold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins.
These are used for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Astonea Labs Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Astonea Labs Ltd or Mono Pharmacare Ltd?

Market cap of Astonea Labs Ltd is 168 Cr while Market cap of Mono Pharmacare Ltd is 23 Cr

What are the key factors driving the stock performance of Astonea Labs Ltd and Mono Pharmacare Ltd?

The stock performance of Astonea Labs Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astonea Labs Ltd and Mono Pharmacare Ltd?

As of May 4, 2026, the Astonea Labs Ltd stock price is INR ₹160.05. On the other hand, Mono Pharmacare Ltd stock price is INR ₹13.25.

How do dividend payouts of Astonea Labs Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Astonea Labs Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.